Senior sales management invest in Redsense Medical AB
Two members of Redsense Medical’s senior sales management have exercised their rights to buy shares in the Company under a personal incentive programme adopted in 2016 through an agreement between them and Redsense Medical’s CEO, Patrik Byhmer.
Brendan Kane, Redsense’s U.S. Director of Sales, and Sebastien Bollue, Redsense’s Director of Commercial Operations globally and responsible for distributors in the EU, have invested in the Company by purchasing 50,000 shares each. The right to aquire shares was given to them when they joined the Company in 2016 as a personal incentive programme; the transaction entails that Patrik Byhmer’s own ownership in the Company is diluted, and no new issue of shares is carried out in conjunction with the personal incentive programme.
”At all times, a growing and innovating company such as Redsense Medical stands and falls by the expertise and trust of its key personnel; it has always been essential for me to find and recruit the best possible members to the team, to propel theorganization forward and developits full potential, and this scheme was a means to accomplish that. I welcome the decision by Brendan and Sebastien to invest and see it as a token of their commitment to the company’s future and our common objectives,”says Patrik Byhmer, CEO of Redsense Medical AB.
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.